{"filing":{"accession_number":"0001743881-26-000026","cik":"0001743881","ticker":"BBIO","company_name":"BridgeBio Pharma, Inc.","form":"8-K","filing_date":"2026-08-10","report_date":"2026-08-10","primary_document":"bbio-20260810.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1743881/000174388126000026/bbio-20260810.htm"},"events":[{"id":26515,"run_id":24101,"accession_number":"0001743881-26-000026","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"BridgeBio disclosed its financial results for Q2 2026 ended June 30, 2026, reporting $243.7 million in total revenues ($222.4 million from Attruby product sales) and providing a comprehensive press release (Exhibit 99.1) with financial and operational updates. This is a standard earnings release disclosure under Item 2.02, material to investors assessing the company's commercial performance and pipeline progress.","company_name":"BridgeBio Pharma, Inc.","ticker":"BBIO","filing_date":"2026-08-10","form":"8-K","submitted_at":null,"items":[{"id":27667,"accession_number":"0001743881-26-000026","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"BridgeBio disclosed its financial results for Q2 2026 ended June 30, 2026, reporting $243.7 million in total revenues ($222.4 million from Attruby product sales) and providing a comprehensive press release (Exhibit 99.1) with financial and operational updates. This is a standard earnings release disclosure under Item 2.02, material to investors assessing the company's commercial performance and pipeline progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:07:08.359009+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27667,"accession_number":"0001743881-26-000026","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"BridgeBio disclosed its financial results for Q2 2026 ended June 30, 2026, reporting $243.7 million in total revenues ($222.4 million from Attruby product sales) and providing a comprehensive press release (Exhibit 99.1) with financial and operational updates. This is a standard earnings release disclosure under Item 2.02, material to investors assessing the company's commercial performance and pipeline progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:07:08.359009+00:00","company_name":"BridgeBio Pharma, Inc.","ticker":"BBIO","filing_date":"2026-08-10"}]}